Avant Immunotherapeutics, Inc.

Needham, MA 02494

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $442K
First Award Date 09/05/86
Most Recent Award Date 07/01/02

Key Personnel

Last Name Name Awards Contact
Pickering Lulu Pickering 1
Makrides Savvas C Makrides 1
Thomas Lawrence J Thomas 2
Rittershaus Charles Rittershaus 2
Kochi Sims K Kochi 1
Beattie David T Beattie 1
Pettey Carolyn L Pettey 1

9 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-AI-02-05
Budget: 07/01/02 - 12/31/03

DESCRIPTION (provided by applicant): The ability to prepare anthrax spores inexpensively and deliver them in an aerosol form, and the high mortality rate of inhalation anthrax, has made Bacillus anthracis one of the most feared agents of biological warfare and terrorism. Despite recent advances in understanding anthrax, no sustained effort has ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/20/00 - 03/20/02

Stroke is the greatest cause of severe disability in western countries. Recently, one thrombolytic therapy has been approved for acute stroke-- rtPA. This treatment must be administered within 3 hours of stroke onset, limiting its general usefulness. The long term objective of the research in this proposal is to develop sCRl sLex to be used alon...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-98-073
Budget: 08/01/00 - 07/31/02

DESCRIPTION (Adapted from Applicant's Abstract): A replication defective HSV-2 strain has been constructed for use as a vaccine for genital herpes. The vaccine strain contains defined deletions in two genes essential for viral replication (UL29 and UL5). The virus is grown on complementing cells that express...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/98 - 08/31/99

Atherosclerosis is a leading cause of morbidity and mortality. Epidemiological and genetic data have shown convincingly: that low levels of HDL or apoAI are associated with increased risk of developing coronary heart disease (CHD). In contrast, high levels of HDL are protective a...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/98 - 01/31/99

Atherosclerosis is a leading cause of morbidity and mortality. The long- term objective of this grant proposal is to evaluate a vaccine that may induce a shift in the lipoprotein profile from an atherogenic one (high LDL, low HDL) to a less-atherogenic one (low LDL, high HDL) and consequently reduce the...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/97 - 08/31/98

Atherosclerosis is a leading cause of morbidity and mortality. Epidemiological and genetic data have shown convincingly: that low levels of HDL or apoAI are associated with increased risk of developing coronary heart disease (CHD). In contrast, high levels of HDL are protective a...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/97 - 03/31/98

Atherosclerosis is a leading cause of morbidity and mortality. The long- term objective of this grant proposal is to evaluate and develop a vaccine that may induce a shift in the lipoprotein profile from an atherogenic one (high LDL low HDL) to a non-atherogenic one (low LDL, high HDL) and consequen...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/96 - 02/28/97

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/05/86 - 02/28/87

The long term objective of this project is to understand the molecular basis of T cell recognition of tumor antigens of lung carcinoma. The specific aims of the proposed study are 1). to characterize the genes encoding T cell antigen receptors (TCAR) from the tumor infiltrating lymphocytes; 2). to investigate whether there is a limited expressi...